Y. Kasamon

发表

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

R. Wahl, M. Lodge, H. Jacene, 2009, Journal of Nuclear Medicine.

FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome

Lei Nie, Richard Pazdur, R. Pazdur, 2019, Clinical Cancer Research.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

G. Rosner, C. Huff, M. Zahurak, 2017, Blood advances.

Immunotherapies for Hodgkin's lymphoma.

Y. Kasamon, R. Ambinder, 2008, Critical reviews in oncology/hematology.

Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography

Y. Kasamon, 2010, Advances in hematology.

Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, Christopher G. Kanakry, G. Rosner, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.

C. Wilson, C. Slingluff, M. Lotze, 1998, Journal of immunology.

FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma

R. Pazdur, G. Reaman, Y. Kasamon, 2022, Pediatric blood & cancer.

FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy

R. Wahl, L. Swinnen, Y. Kasamon, 2004, Current opinion in oncology.

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

T. Habermann, Richard J. Jones, J. Herman, 2012, Blood.

FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma

R. Pazdur, Y. Kasamon, A. Farrell, 2017, The oncologist.

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics.

J. Vose, J. Friedberg, B. Cheson, 2014, Clinical immunology.

Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia

Steve Y. Cho, C. Huff, M. Borowitz, 2013, Leukemia & lymphoma.

gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells

V. Brusic, J. Sidney, A. Sette, 2001, British Journal of Cancer.

Blood or marrow transplantation for mantle cell lymphoma

Y. Kasamon, 2007, Current opinion in oncology.

FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

R. Pazdur, Y. Kasamon, M. Theoret, 2021, The oncologist.

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma

Amy McKee, R. Pazdur, B. George, 2018, Clinical Cancer Research.

Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia

Richard J. Jones, C. Griffin, D. Gladstone, 2011, Leukemia & lymphoma.

Management of symptomatic, untreated chronic lymphocytic leukemia.

I. Flinn, Y. Kasamon, 2007, Blood reviews.

Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma

D. Gladstone, N. Ghosh, Y. Kasamon, 2014, Annals of Hematology.

Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.

R. Wahl, Richard J. Jones, Y. Kasamon, 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Treatment advances in adult Burkitt lymphoma and leukemia

L. Swinnen, Y. Kasamon, 2004, Current opinion in oncology.

Y. Kasamon, R. Ambinder, 2005, Hematology/oncology clinics of North America.

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

R. Pazdur, Y. Kasamon, G. Blumenthal, 2019, The oncologist.

Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcoma

M. Borowitz, Richard J. Jones, J. Bolaños-Meade, 2013, Leukemia & lymphoma.

HHV-8-positive and EBV-positive intravascular lymphoma: an unusual presentation of extracavitary primary effusion lymphoma.

E. Fishman, J. Taube, M. Borowitz, 2014, The American journal of surgical pathology.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

R. Varadhan, C. Huff, M. Zahurak, 2017, Blood.

The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.

Richard J. Jones, C. Griffin, D. Gladstone, 2012, Clinical lymphoma, myeloma & leukemia.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

W. Wilson, Y. Oki, F. Turturro, 2018, Haematologica.

Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL).

T. Habermann, L. Swinnen, H. Jacene, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonotypic B Cells Circulate in Hodgkin’s Lymphoma (HL).

M. Siedner, Richard J. Jones, Y. Kasamon, 2006 .

Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome

C. Huff, J. Lode, J. Kowalski, 2010 .

High-Dose Cyclophosphamide (Cy), Rituximab, and a Cancer Vaccine for Relapsed Classical Hodgkin's Lymphoma (cHL)

M. Borowitz, Richard J. Jones, L. Swinnen, 2010 .

Circulating clonotypic B cells in classic Hodgkin lymphoma.

M. Siedner, Richard J. Jones, Carole B. Miller, 2009, Blood.

High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas

I. Flinn, C. Huff, M. Zahurak, 2011, Leukemia & lymphoma.

EBV‐associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency

Y. Kasamon, A. Nascimento, Thanh N. Nguyen, 2002, American journal of hematology.

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

Alan M. Miller, L. Gordon, R. Fisher, 2008, Transplantation.

Outcomes of Allogeneic Blood or Marrow Transplantation for Peripheral T-Cell Lymphoma.

Richard J. Jones, D. Gladstone, L. Swinnen, 2012 .

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

Amy McKee, R. Pazdur, Y. Kasamon, 2018, The oncologist.

Mean genes and the biology of aggression: a critical review of recent animal and human research.

E. Balaban, J. S. Alper, Y. Kasamon, 1996, Journal of neurogenetics.

Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies.

Elias T. Zambidis, Shannon R. McCurdy, Allen R. Chen, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

Shannon R. McCurdy, G. Rosner, C. Huff, 2017, Haematologica.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Blood.

Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.

Y. Kasamon, E. Fuchs, Ashley T. Munchel, 2011, Best practice & research. Clinical haematology.

Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients

C. Thoburn, B. Smith, Y. Kasamon, 2018, Leukemia & lymphoma.

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

R. Bociek, F. Hernandez-Ilizaliturri, A. Younes, 2016, Haematologica.

Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.

R. Varadhan, Richard J. Jones, L. Swinnen, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.

S. Terezakis, Y. Kasamon, 2012, Critical reviews in oncology/hematology.

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

J. Kowalski, K. Murphy, Richard J. Jones, 2010, Clinical Cancer Research.

Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies.

A. Zachary, Richard J. Jones, D. Gladstone, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

C. Huff, J. Kowalski, Richard J. Jones, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

G. Rosner, C. Huff, M. Zahurak, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Shannon R. McCurdy, G. Rosner, C. Huff, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

I. Flinn, C. Huff, Richard J. Jones, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

Richard J. Jones, C. Kesserwan, Y. Kasamon, 2011, Pediatric reports.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Allen R. Chen, S. Goodman, C. Huff, 2010, Blood.

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

C. Huff, Richard J. Jones, D. Gladstone, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.

Daniel I. S. Rosenbloom, R. Siliciano, J. Gallant, 2020, The lancet. HIV.

Allogeneic Bone Marrow Transplant for HIV Patients with Hematologic Malignancies with Post-transplant Cyclophosphamide: a Feasibility Study

Daniel I. S. Rosenbloom, R. Siliciano, J. Gallant, 2020 .

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

G. Rosner, C. Huff, M. McDevitt, 2014, Blood.

Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,

Allen R. Chen, Richard J. Jones, Y. Kasamon, 2011 .

Richard J. Jones, D. Gladstone, J. Bolaños-Meade, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose cyclophosphamide as single agent, short-course prophylaxis of graft-

Allen R. Chen, C. Huff, M. Zahurak, 2017 .

of graft-versus-host disease High-dose cyclophosphamide as single-agent, short-course prophylaxis

Allen R. Chen, M. Zahurak, Richard J. Jones, 2013 .

HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide.

Shannon R. McCurdy, M. Grunwald, Stephanie J. Lee, 2021, Blood.

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

Zhe Zhang, I. Flinn, R. Abrams, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide

G. Rosner, C. Huff, M. Zahurak, 2016, Leukemia & lymphoma.

FDA’s Oncology Center for Excellence Pilots Project Orbis: A framework for concurrent submission and review of oncology products among international partners.

K. Goldberg, R. Pazdur, Y. Kasamon, 2020 .

Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas.

Richard J. Jones, S. Gore, A. Blackford, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

K562/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) patients (PTS) with residual disease on imatinib mesylate (IM).

J. Kowalski, B. Smith, Y. Kasamon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

J. Kowalski, K. Murphy, Richard J. Jones, 2005 .

FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma

R. Wahl, Y. Kasamon, 2008, Current opinion in oncology.

Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.

I. Flinn, R. Abrams, Richard J. Jones, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

G. Rosner, C. Huff, Richard J. Jones, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia

S. Goodman, M. Grever, J. Byrd, 2005, Clinical Cancer Research.

MAGE-6 encodes HLA-DRbeta1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma.

Vladimir Brusic, John Sidney, Alessandro Sette, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement.

I. Flinn, R. Abrams, S. Piantadosi, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen

C. Huff, Richard J. Jones, B. Smith, 2009, Bone Marrow Transplantation.

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

S. Goodman, R. Wahl, M. Borowitz, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The HDAC Inhibitor Entinostat (SNDX-275) Induces Clinical Responses in Patients with Relapsed and Refractory Hodgkin's Lymphoma: Results of ENGAGE-501 Multicenter Phase 2 Study

R. Bociek, A. Younes, Y. Kasamon, 2011 .

Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma

R. Wahl, S. Piantadosi, H. Jacene, 2017, Molecular Imaging and Biology.

The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.

R. Pazdur, Y. Kasamon, N. Gormley, 2022, The Lancet. Oncology.

Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival.

R. Pazdur, Y. Kasamon, M. Theoret, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma

R. Wahl, E. Frey, Richard J. Jones, 2013, The Journal of Nuclear Medicine.

Phase I/II Dose-Escalation Study of Tositumomab and Iodine I 131 Tositumomab for Relapsed/Refractory Classical or Lymphocyte-Predominant Hodgkin’s Lymphoma: Feasibility and Initial Safety

R. Wahl, H. Jacene, Y. Kasamon, 2008 .

HLA-Haploidentical Bone Marrow Transplantation (BMT) for High Risk Hematologic Malignancies Using Myeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

Allen R. Chen, M. Zahurak, Richard J. Jones, 2010 .

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

Shannon R. McCurdy, G. Rosner, C. Huff, 2015, Blood.

Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.

R. Varadhan, Richard J. Jones, J. Bolaños-Meade, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

L. Gordon, R. Fisher, T. Grogan, 2008, Transplantation.

Desensitization for Mismatched Hematopoietic Stem Cell Transplantation (HSCT)

A. Zachary, Richard J. Jones, D. Gladstone, 2011 .

Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

S. Goodman, R. Wahl, M. Borowitz, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

Richard J. Jones, C. Kesserwan, Y. Kasamon, 2011, Pediatric reports.

Nonmyeloablative HLA-Haploidentical (NMA Haplo) BMT with High-Dose Posttransplantation Cyclophosphamide (PTCy) Is Associated with Similar Outcomes to Matched BMT When Stratified By Disease Risk Index (DRI)

Shannon R. McCurdy, C. Huff, Richard J. Jones, 2014 .

Graft-Versus-Host Disease (GVHD) and Survival Outcomes after HLA-Haploidentical (Haplo) Bone Marrow Transplant (BMT) Compare Favorably with Matched Related Donor (MRD), and Matched Unrelated Donor (MUD) BMT Utilizing High-Dose Posttransplantation Cyclophosphamide (PTCy)

Shannon R. McCurdy, G. Rosner, Richard J. Jones, 2014 .

Encouraging Outcomes In Older Patients (Pts) Following Nonmyeloablative (NMA) Haploidentical Blood or Marrow Transplantation (haploBMT) With High-Dose Posttransplantation Cyclophosphamide (PT/Cy)

Richard J. Jones, J. Bolaños-Meade, Y. Kasamon, 2013 .

Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

I. Flinn, C. Huff, Richard J. Jones, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.